April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization - RII
Author Affiliations & Notes
  • Belquiz A Nassaralla
    Cataract Cornea & Refractive Surgery, Instituto de Olhos de Goiania, Goiania, Brazil
  • Arthur A Nassaralla
    Faculdade de Medicina, SLM, Campinas, Brazil
  • Joao J Nassaralla
    Faculdade de Medicina, UFG, Goiania, Brazil
  • Joao J Nassaralla
    Retina and Vitreous, Instituto de Olhos de Goiania, Goiania, Brazil
  • Footnotes
    Commercial Relationships Belquiz Nassaralla, None; Arthur Nassaralla, None; Joao Nassaralla, None; Joao Nassaralla, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4958. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Belquiz A Nassaralla, Arthur A Nassaralla, Joao J Nassaralla, Joao J Nassaralla; Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization - RII. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4958.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV).


8 patients with subfoveal PM-CNV, were treated with of 2 mg ( 0.05mL) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. AII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 1 year.


The mean age of the study patients was 28 years (25-43) and the mean refractive error -13.50 D. At 12 months post-treatment, mean VA increased from 20/100 (20/400 -20/40) to 20/50 (20/200-20/30). Only 2 patients lost 35 letters due to macular atrophy; the other 6 increased or stabilized their VA. Mean macular thickness decreased from 332 to 255 µm. No ocular or general side effects were recorded.


These short-term results suggest that AII are effective and safe in patients with PM-CNV. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Keywords: 605 myopia • 700 retinal neovascularization • 503 drug toxicity/drug effects  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.